Latest event summaries
Event summaries combining transcripts, slides, and related documents. Updated as new events are published.
- All motions passed, directors elected, auditors appointed, and 2025 financials tabled.LCFS
AGM 2026 - All director nominees and the auditor appointment were approved; no shareholder questions were raised.ACIC
AGM 2026 - All proposals passed, directors elected, and no stakeholder questions were raised.SKYE
AGM 2026 - Q1-2026 saw 3% revenue growth, improved margins, and continued positive Adjusted EBITDA.TRBE
Q1 2026 - Oral therapy for Stargardt disease nears FDA submission after strong phase III results.BLTE
Stifel 2026 Virtual Ophthalmology Forum - OP-3136 and palazestrant advance in trials, targeting major oncology markets with strong differentiation.OLMA
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Directors were elected, auditors reappointed, and executive compensation approved.FUN
AGM 2026 - Directors were elected, executive pay approved, and auditor ratified, with board transitions announced.VIR
AGM 2026 - All proposals passed, including director elections and auditor ratification, with no stockholder questions.EXEL
AGM 2026 - IBTROZI's strong first-line growth and pipeline progress drive optimism for future expansion.NUVB
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - OMNI and TearCare drive growth with innovation, strong execution, and expanding market opportunities.SGHT
Stifel 2026 Virtual Ophthalmology Forum - Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions.CBIO
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Strong Q1 2026 results with robust profit, logistics expansion, and a PLN 6.00 dividend recommendation.UNT
Q1 2026 - Q1 2026 delivered strong profit growth, margin expansion, and a pending major acquisition.BRIM
Q1 2026 - Record acquisitions and fintech merger fueled €195M output and €49M EBITDA, setting up strong 2026.CHG
H2 2025 - Darovasertib shows strong results in uveal melanoma; broad pipeline progress and key data updates are expected.IDYA
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA